Advertisement


Related Videos

Deborah Collyar: What's In It for Patients?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




Advertisement